Gufic BioSciences Ltd's Q4FY25 Quarter Results
- 31 May 2025
Result Summary
- Gufic BioSciences Ltd reported a 6.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a - of -.
- Its expenses for the quarter were down by 8.0% QoQ and - - YoY.
- The net profit increased 3.8% QoQ and - - YoY.
- The earnings per share (EPS) of Gufic BioSciences Ltd stood at 2 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 195.87 | 209.66 | 0.00 | -6.6% | - |
Total Expenses | 168.76 | 183.40 | 0.00 | -8.0% | - |
Profit Before Tax | 27.12 | 26.26 | - | 3.3% | NaN% |
Tax | 7.07 | 6.96 | 0.00 | 1.6% | - |
Profit After Tax | 20.05 | 19.31 | 0.00 | 3.8% | - |
Earnings Per Share | 2.00 | 1.90 | 0.00 | 5.3% | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Gufic BioSciences Ltd is a pharmaceutical company known for its production of a wide range of pharmaceutical and healthcare products. The company operates in the biotechnology and pharmaceutical industry, focusing on the development, manufacturing, and marketing of various pharmaceutical formulations. Gufic BioSciences is involved in the production of Active Pharmaceutical Ingredients (APIs), formulations, herbal products, and healthcare products. While specific recent developments for the company are not provided here, companies in this sector often engage in research and development to innovate or enhance their product offerings and expand their market reach.
Revenue
In Q4FY25, Gufic BioSciences Ltd reported a total income of ₹195.87 crores, which represents a decrease of 6.6% from ₹209.66 crores in Q3FY25. There is no year-over-year (YoY) comparison available as the data for Q4FY24 is not provided. The company’s revenue performance over the quarter shows a contraction, reflecting a lower income generation in the most recent quarter compared to the previous one. This change in revenue could be subject to various factors such as market demand, pricing strategies, or product sales mix.
Profitability
For Q4FY25, the Profit Before Tax (PBT) was recorded at ₹27.12 crores, showing a quarter-over-quarter (QoQ) increase of 3.3% from ₹26.26 crores in Q3FY25. The tax expense for the quarter was ₹7.07 crores, which also saw a slight increase of 1.6% compared to ₹6.96 crores in the previous quarter. Consequently, the Profit After Tax (PAT) for Q4FY25 was ₹20.05 crores, reflecting a 3.8% rise from ₹19.31 crores in Q3FY25. The Earnings Per Share (EPS) also increased by 5.3% to ₹2.00 from ₹1.90 in the preceding quarter. These figures highlight the profitability aspects of the company for the quarter, with improvements in net income and earnings per share.
Operating Metrics
The total expenses for Gufic BioSciences Ltd in Q4FY25 amounted to ₹168.76 crores, which is a decrease of 8.0% from ₹183.40 crores in Q3FY25. This reduction in expenses contributed to the enhanced profitability despite the decline in total income. The data does not provide a direct year-over-year comparison for operating metrics, but the quarter-over-quarter analysis indicates changes in cost management and operational efficiency. Key financial ratios such as the Price to Earnings (P/E) ratio, debt-to-equity ratio, or current ratio are not calculable with the given data, as additional market information or balance sheet data is necessary to derive these metrics. Nonetheless, the reduction in expenses relative to the income decrease suggests potential shifts in the company's operational strategies or cost structure.